NCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
Clinical Trials
179 trialsNCT04716153 2026-01-20
RE-NEZ-SENS
University Hospital, Montpellier
Phase NA Terminated
NCT04940468 2026-01-14
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
University of Colorado, Denver
Phase NA Terminated
NCT03283423 2026-01-09
Image-guided Lymphadanectomy in AMIGO
Brigham and Women's Hospital
Phase NA Terminated
NCT03856216 2025-10-16
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06275854 2025-10-14
YASU Research Registry: For Young Adults With Cancer
Young Adult Survivors United
Terminated
NCT01258933 2025-10-01
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04473937 2025-09-24
Radiation Post-CAR T in Refractory Lymphoma
Massachusetts General Hospital
Phase NA Terminated
NCT05655546 2025-08-08
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
Phase NA Terminated
NCT03862131 2025-07-29
PROACT
Washington University School of Medicine
Phase 2 Terminated
NCT02681302 2025-07-25
CPIT001
Hackensack Meridian Health
Phase 1/2 Terminated
NCT05010369 2025-06-26
DOLPHIN-VIVO
University of Exeter
Phase NA Terminated
NCT02811679 2025-05-23
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT01532635 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Phase 2 Terminated
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated
NCT00848328 2025-04-24
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Terminated
NCT02291965 2025-03-03
Blood Samples to Identify Biomarkers of Busulfan
Fred Hutchinson Cancer Center
Terminated
NCT03636503 2025-02-06
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03789864 2024-05-22
BDI
Indiana University
Phase NA Terminated
NCT02624388 2024-05-06
UVA-Gen001
University of Virginia
Phase 2 Terminated
NCT02282358 2024-03-08
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT04465760 2024-01-24
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00006478 2023-09-18
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Terminated
NCT00074165 2023-07-06
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01307605 2023-06-27
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
Swiss Cancer Institute
Phase 2 Terminated
NCT01378871 2023-06-09
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03850171 2023-02-27
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Insel Gruppe AG, University Hospital Bern
Phase NA Terminated
NCT05271279 2022-11-02
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
Beijing Boren Hospital
Phase EARLY_PHASE1 Terminated
NCT04423848 2022-10-28
Home Hospital for Lymphoma
Massachusetts General Hospital
Phase NA Terminated
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated
NCT02898259 2022-09-26
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT00858793 2022-09-08
High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Terminated
NCT02414724 2022-07-25
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
Roswell Park Cancer Institute
Phase 1 Terminated
NCT00968864 2022-04-22
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00785798 2022-04-04
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Yale University
Phase 1/2 Terminated
NCT02356458 2022-03-11
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 1/2 Terminated
NCT01685606 2022-03-04
273
Brown University
Phase 2 Terminated
NCT03137537 2022-02-10
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00637832 2022-01-06
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
Phase 2 Terminated
NCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT03588936 2021-10-11
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
Phase 1 Terminated
NCT03849950 2021-09-30
Self-Management and Activation to Reduce Treatment-Related Toxicities (SMARTCare)
University Health Network, Toronto
Phase NA Terminated
NCT03585725 2021-09-27
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
Weill Medical College of Cornell University
Phase EARLY_PHASE1 Terminated
NCT04253223 2021-06-11
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib
Duke University
Phase 1 Terminated
NCT02499627 2021-05-27
FIL-BBV
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
NCT03465891 2021-01-12
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00981799 2020-10-01
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT00506948 2020-09-24
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00726830 2020-09-24
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00303719 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated